Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EPS (Basic) (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of EPS (Basic) data on record, last reported at $0.2 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 25.0% year-over-year to $0.2; the TTM value through Dec 2025 reached $3.1, up 1723.53%, while the annual FY2025 figure was $3.1, 1837.5% up from the prior year.
  • EPS (Basic) reached $0.2 in Q4 2025 per TGTX's latest filing, down from $2.68 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.68 in Q3 2025 and bottomed at -$0.7 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$0.05, with a median of -$0.18 recorded in 2022.
  • Peak YoY movement for EPS (Basic): plummeted 96.25% in 2024, then soared 8833.33% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.7 in 2021, then rose by 18.57% to -$0.57 in 2022, then soared by 84.21% to -$0.09 in 2023, then surged by 277.78% to $0.16 in 2024, then rose by 25.0% to $0.2 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $0.2 in Q4 2025, $2.68 in Q3 2025, and $0.19 in Q2 2025.